The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models
On January 12, 2026, PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that it believes will position long-read whole-genome sequencing as enabling infrastructure to support the development of individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases. Under the proposed collaboration, PacBio will provide its scientific expertise, and the collaboration will utilize PacBio’s long-read whole genome sequencing technology, to study the design, feasibility assessment, and molecular characterization of ASO therapies – to help extend the role of long-read genomics for those who may lack effective treatment options.
ASO therapies require a complete understanding of the genomic architecture, including variant phasing, structural variation, repeat expansions, and regulatory alterations that are frequently missed or unresolved by standard sequencing approaches. By integrating long-read whole-genome sequencing earlier in the therapeutic development process, the proposed collaboration will aim to reduce the need for multiple sequential tests, accelerate target validation, and improve confidence in ASO design.
Under the proposed collaboration, PacBio will donate sequencing reagents and provide expert scientific resources to support long-read genome analysis for research to further development of therapeutic treatments for individuals with rare diseases. These efforts are intended to directly inform target identification, ASO design feasibility, and regulatory-grade molecular characterization, strengthening the end-to-end pipeline from genomic discovery to enabling development of therapeutic interventions.
“Rare disease therapies demand a level of genomic resolution that simply isn’t achievable with fragmented testing approaches,” said Christian Henry, President and CEO of PacBio. “By working with n-Lorem and EspeRare under the proposed collaboration, we aim to establish HiFi long-read whole genome sequencing as the preferred platform for precision therapeutic development in rare disease, where understanding the full complexity of the genome is essential to designing safe and effective interventions.”
n-Lorem Foundation is a nonprofit organization dedicated to discovering, developing, and providing free, individualized ASO therapies for patients with rare genetic diseases, often under patient-specific regulatory pathways. The EspeRare foundation works to unlock and advance translational infrastructure, partnerships, and patient access to novel therapeutics across rare disease communities. Together, the organizations represent a complementary ecosystem spanning patient identification, molecular characterization, therapy development, and clinical implementation.
“n-Lorem was founded to discover, develop, manufacture, and provide experimental ASO treatments to patients with the rarest genetic mutations for free, for life. To bring genetic medicines to patients with extremely rare genetic diseases, the first step is to understand the genomic architecture of each patient,” said Stanley T. Crooke, MD, PhD, Founder, Chairman and CEO, n-Lorem Foundation. “PacBio’s generous donation of long-read sequencing for many patients each year will enhance our ability to meet the extraordinary demand from the nano-rare community. It exemplifies the heart of the therapeutic industry, and it adds to the generosity of so many companies in our industry that have stepped up to help n-Lorem do what seemed impossible six years ago.”
“PacBio’s long-read sequencing technology enables the level of genomic understanding required to guide care in rare diseases,” said Caroline Kant, Founder and Executive Director of EspeRare. “Through the proposed collaboration we will be able to translate complex genomic information into therapies tailored to each patient’s biology, bringing groundbreaking treatments to families who urgently need them.”
As individualized and n-of-1 therapeutic models gain momentum across the biopharma industry, PacBio aims to play a central role in supporting scalable, genomics-driven therapy development, where complete and accurate genome characterization is foundational to developing treatment options.
The proposed collaboration reflects PacBio’s broader commitment to advancing human health through technologies that enable deeper biological insight and support the development of potential actionable outcomes.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About n-Lorem Foundation
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility, and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 380 applications for treatment with more than 200 nano-rare patients approved and more than 30 patients on treatment. n-Lorem was founded by Stanley T. Crooke, MD, PhD, former Chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube. To learn more about n-Lorem’s mission visit us at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to nano-rare patients in need.
About EspeRare
EspeRare is a nonprofit organization dedicated to advancing therapies for patients with rare diseases through strategic partnerships, translational infrastructure, and patient-centered programs. After a decade of removing drug development barriers that prevent promising science from reaching historically overlooked patients, EspeRare has become a pioneer in prenatal and personalized therapies for rare diseases. Combining biotech agility with a mission-driven model, EspeRare bridges the translational “valley of death” by aligning patient communities, academics, commercial partners, and regulators to advance treatments and support equitable access. Based in Geneva, EspeRare leverages its position at the crossroads of science, health diplomacy, and the life science industry to structure collaborations that unlock innovative therapies and maximize global patient impact.
